AI Article Synopsis
- Researchers discovered that GM2AP, a new adipokine, disrupts insulin signaling in cultured cells.
- When injected into mice, GM2AP lowered blood glucose levels and increased insulin while reducing glucose, leptin, and free fatty acids after 10 days.
- GM2AP also stimulated calcium influx and insulin secretion in hamster insulinoma cells, and blocking GM2AP with antibodies reduced its insulin-secreting effect, highlighting its role in obesity.
Article Abstract
Recently, we identified ganglioside GM2 activator protein (GM2AP) as a novel adipokine, and revealed that treatment of cultured cells with GM2AP impairs insulin signal transduction. The aim of this study was to examine the impact of GM2AP on glucose metabolism in vivo. Injection of recombinant GM2AP in mice significantly lowered blood glucose levels in glucose tolerance tests. Administration of GM2AP to mice for 10 days increased serum insulin levels, whereas the contents of glucose, leptin and FFA were significantly decreased. Stimulation of calcium influx and insulin secretion by GM2AP was observed in hamster insulinoma HIT-T15 cells. Blockage of GM2AP function by specific antibodies inhibited GM2AP-induced insulin secretion. These results provide novel insights into the physiological functions of GM2AP in obesity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.febslet.2011.07.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!